WuXi XDC Cayman, Inc. · HKEX:2268
WuXi XDC Cayman — WuXi XDC — FY2023 Earnings Presentation
31 slides from WuXi XDC Cayman's earnings presentation, Mar 26, 2024
Slide 1: WuXi XDC 2023 Annual Results
Linking innovation to health WuXi XDC 2023 Annual Results 26 March, 2024
Slide 2: Disclaimer
Disclaimer Forward-Looking Statements This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although
Slide 3: Contents
CONTENTS 01 2023 Annual Results Key Takeaways Dr. Jimmy (Jincai) LI, CEO 02 Financial Performance Mr. Michael (Xiaojie) XI, CFO 03 Q&A All
Slide 4: 2023 Annual Results Key Takeaways
01 2023 Annual Results Key Takeaways Dr. Jimmy (Jincai) LI, CEO
Slide 5: WuXi XDC: Global Leading Integrated CRDMO Dedicated to ADC and Bioconjugates
WuXi XDC: Global Leading Integrated CRDMO Dedicated to ADC and Broader Bioconjugates Market Our Vision: “Linking innovation to health” in the global ADC (antibody drug conjugate) and XDC (other novel bioconjugate) industry Foundation & Listing: U.S. Wuxi West Coast East Coast China Shanghai - Establ
Slide 6: Our Achievements - Recognitions from Industry and Investors
Our Achievements - Recognitions from Industry and Investors Best CDMO Prize at the 2023 World ADC Awards “Best IPO”of Year 2023 • The largest healthcare IPO in the past WuXi XDC two years Named the Winner of the • Listed on Hong Kong Main board, “Best CDMO” raising US$520mn in total (post-shoe) at t
Slide 7: Solid Operational Progress and Remarkable Financial Results
Solid Operational Progress and Remarkable Financial Results 01 02 03 Project Portfolio Capabilities and Significant and Customers Capacities Financial Growth Our Capacities 143 iCMC projects • All-in-One manufacturing • Revenue: facilities operational in the 2,124 Mn RMB, New integrated Wuxi city si
Slide 8: Powerful Platform and Business Model to Secure Project Wins and Fuel Growth
Powerful Platform and Business Model to Secure Project Wins and Fuel The Growth Number of Projects Through “Enable – Follow – Win” Strategy “R” "Research”: Enable discovery to PCC 427 Discovery(1) / 299 (3) 36 projects advanced from discovery to iCMC stage (1) 84 Preclinical / 57 (3) "Development":
Slide 9: High-Quality Customer Portfolios Including Global Pharma and Biotechs
Our High-Quality Customer Portfolios Including Global Pharma Companies & Innovative Biotechs A Fast-Growing Customer Base… …With Significant Presence of Cumulative “Top 10 Global Pharma Companies” (1) 345 265 6 out of 10 24% Partnered with WuXi Composing 24% of 2022 2023 XDC(2) 2023 total revenue Ra
Slide 10: Leading Technology Platform: Diverse Solutions From 10,000+ Molecules
Our Vastly Experienced and Leading Technology Platform: Unmatched Diverse Solutions From 10,000+ Molecules .. With Various Targets and Experience Diversified Projects .. Payload-linker Technology Diversified Targets ADC Ongoing Projects 10,000+ HER3 CLDN18.2 Bioconjugate molecules CLDN6 ROR1 322 129
Slide 11: Solidifying Technology Leadership Through Open Platform and Partnerships
Further Solidifying Technology Leadership Through Open Platform and Partnerships Conjugation and Payload-linker Technologies on WuXi XDC Platform ✓ In-house developed ✓ Mastery of Technology ✓ External Partnerships ✓ Broad Payload-Linker 10+ • iGDC (intelligent Glycotransferase • Interchain re-bridg
Slide 12: Continuously Enhancing Our WuXiDARx Technology
Continuously Enhancing Our WuXiDARx Technology • Interchain cysteine conjugation are the most clinically validated conjugation sites (9 out of 15 approved ADCs used these sites). • To better utilize these conjugation sites, we introduce WuXiDARx which has the following advantages: D2 D4 D6 D2 D4 D0
Slide 13: Our Powerful Platform: From DNA to IND in < 15 months
Our Powerful Platform: From DNA to IND in < 15 months WuXi XDC Standard Timeline (Months) Industry Average Timeline 24-30Months 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 18 20 22 24 - 30 15 months! Our optimized integrated technology platforms and single-source solution dramatically reduce timelines In
Slide 14: Empowering Clients is Our Core Value - A Successful Case Reviewed
Empowering Clients is Our Core Value - A Successful Case Reviewed The consistently high-quality and full lifecycle service provided by XDC since Duality Bio’s founding XDC provided integrated services for Duality to help facilitate its milestones Late-stage IND filing Resupply development About Dual
Slide 15: All-in-One Manufacturing Facilities Operational and Ramping Up Rapidly
All-in-One Manufacturing Facilities Operational and Ramping Up Rapidly XDC Wuxi Site All-in-One manufacturing facilities with expanded capacity and robust supply chain! The global uniquely designed dual All manufacturing operations are compliant Wuxi site facilities ramps up quickly and functional l
Slide 16: Our Singapore Facility to Deliver Manufacturing Capacity and Global Supply
Empowering Clients Globally: Our Singapore Facility to Deliver Exceptional, Sustainable Manufacturing Capacity and Global Supply Solutions Facilities 2024 • Ground breaking Singapore’s Tuas Biomedical Park 22,000 sq meters • mAb intermediate, 2026 conjugate DS & DP Company management team at Singapo
Slide 17: Our Global GMP-Compliant Manufacturing Facilities
Our Global GMP-Compliant Manufacturing Facilities Changzhou site Shanghai site Wuxi site Discovery & Research Discovery, Development - Antibody intermediate Current capacity: & Manufacturing - Bioconjugate Manufacturing - Payload-linkers Development - Antibody intermediate - Bioconjugate - Payload-l
Slide 18: Workforce Expansion Strategically
Workforce Expansion Strategically: Navigating Leadership, Growth, Experience and Efficiency Expansion of Talent Pool 2023 Key Talents(1) Retention Rate to Support Rapid Business Growth Total headcount 1,178 95.2% 738 High Quality Talents Across All Functions 406 75% 53% Master degree and above compo
Slide 19: We Are Solidly Executing Our Corporate Strategy
We Are Solidly Executing Our Corporate Strategy Continue to improve technologies through internal R&D and strategic partnerships EC H N OLOGY Expand manufacturing Pioneer the industry capacities globally development from ADC to XDC CAPACI Y PIONEE LEADER HIP C STOMER Solidify industry leading positi
Slide 20: Financial Performance
02 Financial Performance Mr. Michael (Xiaojie) XI, CFO
Slide 21: 2023 - Another Year with Outstanding Results
2023 - Another Year with Outstanding Results Revenue Gross Profit RMB mm RMB mm 26.4% 26.3% 2,123.8 559.6 990.4 261.1 FY2022 FY2023 FY2022 FY2023 EBITDA(1) and Adjusted EBITDA(2)(3) Net Profit and Adjusted Net Profit(2)(3) RMB mm RMB mm 26.6% 23.6% 19.6% 19.4% 22.7% 17.5% 15.7% 13.4% 501.2 412.3 263
Slide 22: Robust Growth Underpinned by Post-IND Projects and Strong Backlog
Robust Growth Underpinned by High Percentage of Post-IND Projects and Strong Backlog Number of Projects Through “Enable – Follow – Win” Strategy Revenue by Project Status RMB mm “R” 427 Discovery(1) / 299 (3) 49.0% 38.5% 43.6% 51.0% 61.5% 56.4% 84 Preclinical / 57 (3) 38 Phase I / 27 (3) 1,197.1 59
Slide 23: Robust Growth of Revenue Across All Geographic Regions
Robust Growth of Revenue Across All Geographic Regions North America China Revenue Breakdown by Geography(1) RMB mm RMB mm 851.9 Total Revenue 990.4 2,123.8 (RMB mm) 661.3 Revenue Growth 218.3% 114.4% 444.9 306.2 % of Revenue 44.9% FY2022 FY2023 FY2022 FY2023 40.1% North America 30.9% 31.1% China Eu
Slide 24: Our Mission
24 Our Mission To accelerate and transform the discovery, development and manufacturing of bioconjugates through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide.
Slide 25: Q&A
Q&A Dr. Jimmy (Jincai) LI, CEO Mr. Michael (Xiaojie) XI, CFO
Slide 26: Appendix Financial Statements
Appendix Financial Statements
Slide 27: Consolidated Income Statements
Consolidated Income Statements Year ended December 31 RMB'000 2023 2022 Revenue 2,123,839 990,423 Cost of sales (1,564,281) (729,340) Gross profit 559,558 261,083 Other income 92,305 26,152 Other gains and losses (43,871) 46,672 Impairment losses (recognized) reversed, under expected credit loss mod
Slide 28: Consolidated Balance Sheets
Consolidated Balance Sheets Year ended December 31 RMB'000 2023 2022 Non-current assets Property, plant and equipment 1,246,234 798,575 Investment property 12,409 12,812 Right-of-use assets 2,145 5,280 Goodwill 215,193 215,193 Intangible assets 52,946 50,648 Deferred tax assets 6,267 11,540 Other lo
Slide 29: Consolidated Balance Sheets (Cont'd)
Consolidated Balance Sheets (Cont’d) Year ended December 31 RMB'000 2023 2022 Net current assets (liabilities) 3,920,570 388,358 Total assets less current liabilities 5,455,911 1,482,406 Non-current liabilities Deferred tax liabilities - - Lease liabilities 1,595 1,627 Net assets 5,454,316 1,480,779
Slide 30: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows Year ended December 31 RMB'000 2023 2022 OPERATING ACTIVITIES Profit before tax 359,612 195,801 Adjustments for: Finance costs 742 2,916 Interest income from banks (47,363) (4,612) Depreciation of property, plant and equipment 46,412 17,510 Depreciation of inves
Slide 31: Consolidated Statements of Cash Flows (Cont'd)
Consolidated Statements of Cash Flows (Cont’d) Year ended December 31, RMB'000 2023 2022 INVESTING ACTIVITIES Proceeds on disposal of property, plant and equipment 10,808 1,640 Payments for property, plant and equipment (529,360) (201,382) Payments for intangible assets (10,000) - Receipt of bank in